research use only

HRS-4642 KRAS G12D Inhibitor

Name: HRS-4642
Brand: Selleck Chemicals
SKU: E4651
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E4651

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

HRS-4642 KRas inhibitor Chemical Structure

Quality Control

Batch: E465101 DMSO]190 mg/mL]false]Ethanol]25 mg/mL]false]Water]Insoluble]false Purity: 98.45%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

98.45

Related Targets	ERK p38 MAPK Raf JNK MEK Ras S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
Other KRas Inhibitors	RMC-7977 Daraxonrasib (RMC-6236) MRTX1133 Zoldonrasib (RMC-9805) BI-2852 Adagrasib (MRTX849) ARS-1620 BI-3406 ARS-853 BAY-293

Solubility

In vitro
Batch:

DMSO : 190 mg/mL (300.3 mM) Ultrasonicated;
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 25 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (7.90mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (0.79mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	632.69	Formula	C₃₄H₃₅F₃N₆O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	3033864-81-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	KRAS G12D 0.083 nM(Kd)
References	[1] https://pubmed.ncbi.nlm.nih.gov/38942026/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-15)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07232875	RECRUITING	KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting	Jiangsu HengRui Medicine Co., Ltd.	2025-11-21	PHASE3
NCT07503639	NOT_YET_RECRUITING	Locally Advanced Colorectal Cancer	Fudan University	2026-04	PHASE2
NCT07296341	RECRUITING	Locally Advanced or Metastatic Pancreatic Cancer With	Shanghai Hengrui Pharmaceutical Co., Ltd.	2026-01-08	PHASE1; PHASE2
NCT07691593	NOT_YET_RECRUITING	Pancreatic Cancer	Changhai Hospital	2026-06	PHASE2
NCT07438106	RECRUITING	Locally Advanced Pancreatic Cancer With KRAS G12D Mutation	The First Affiliated Hospital with Nanjing Medical University	2026-01-28	PHASE2
NCT06427239	RECRUITING	Pancreatic Cancer	Fudan University	2024-06-17	PHASE1; PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):